Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Thermo Fisher Scientific (TMO)

Thermo Fisher Q4 2025 revenue rises 7% to $12.21 billion; GAAP EPS up 9% to $5.21

Positive Impact 3 of 5 earnings Written later

Thermo Fisher reported fourth-quarter and full-year 2025 results on January 29, 2026. Revenue and earnings per share both grew from the prior-year periods, though the fourth-quarter adjusted operating margin slipped to 23.6% from 23.9%. The filing contains no 2026 guidance; the company said it will provide that on its earnings call that morning.

Key points

  • Fourth-quarter revenue was $12.21 billion, up 7% from $11.40 billion, with organic revenue growth of 3%.
  • Fourth-quarter GAAP diluted EPS was $5.21, up 9%; adjusted EPS was $6.57, up 8%.
  • Full-year 2025 revenue was $44.56 billion, up 4%; full-year GAAP diluted EPS was $17.74, up 7%.
  • 2026 financial guidance will be given on the earnings conference call at 8:30 a.m. Eastern Time on January 29, 2026.

The filing

CompanyThermo Fisher Scientific (TMO)
Form8-K, current report
Filed with the SECJan 29, 2026, 6:02 AM ET
Accession number0000097745-26-000012

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.